Filing Flows

Filing Flows › Rhythm Pharmaceuticals (RYTM) › Next earnings date

Rhythm Pharmaceuticals (RYTM) earnings: beat the estimate

Rhythm Pharmaceuticals (RYTM) reported on Nov 3, 2026 and beat the EPS estimate: −$0.61 against −$0.74 (+17.8%). Revenue was $92.1M for Q3 2026, +80% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+17.8% vs estimate
Beat rate80%

The last report

Rhythm Pharmaceuticals reported revenue of $92.1M for the third quarter 2026 (+80% Y/Y), net loss $41.4M. How it makes money → · Every quarter →

Rhythm Pharmaceuticals: EPS against the estimate, last 5 reportsRhythm Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$0.73−$0.82Nov 25−$0.78−$0.73Feb 26−$0.86−$0.83May 26−$0.83−$0.73Aug 26−$0.74−$0.61Nov 26
Latest (Nov 26): Estimate −$0.74, Reported −$0.61.

Rhythm Pharmaceuticals' latest quarter

Rhythm Pharmaceuticals, Q3 2026: revenue $92.1M (+80% year over year), operating margin -42.6%, net loss $41.4M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.

Questions

Did Rhythm Pharmaceuticals beat earnings?

Rhythm Pharmaceuticals (RYTM) reported on Nov 3, 2026 and beat the EPS estimate: −$0.61 against −$0.74 (+17.8%).

When does RYTM report earnings?

The next date is not set yet.

Does Rhythm Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.